Keefe, D.Lees, J.Horvath, N.2007-01-152007-01-152006Supportive Care in Cancer, 2006; 14(6):580-5820941-43551433-7339http://hdl.handle.net/2440/23014The original publication can be found at www.springerlink.comGoals of work the aim of this paper was to review the initial use of Palifermin(rHu-KGF1) in a single institution, for the prevention of oral mucositis in high-dose chemotherapy and stem cell transplantation. Methods the case records of the first five patients treated with Palifermin at the Royal Adelaide Hospital Cancer Centre were reviewed, and incidence,severity and duration of the oral mucositis were recorded, as well as demographics and toxicities. Results two of the five patients developed grade 4 mucositis, and the remaining three patients developed grade 2 mucositis. Palifemin was well tolerated with only one patient developing a rash. Conclusions the severity of oral mucositis was less than would be expected in these patients without anti-mucositis therapy. Palifermin was well tolerated. Obviously this single institution report is from a very small cohort of patients, but it is encouraging for the ease of use of this drug in the future.enHumansStomatitisDrug EruptionsBusulfanPodophyllotoxinMelphalanCyclophosphamideCarmustineCytarabineAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeTransplantation ConditioningCombined Modality TherapyHematopoietic Stem Cell TransplantationDrug Administration ScheduleSeverity of Illness IndexIncidencePrimary PreventionTime FactorsAdultMiddle AgedCancer Care FacilitiesSouth AustraliaFemaleMaleFibroblast Growth Factor 7Journal article002006078510.1007/s00520-006-0048-30002383182000142-s2.0-3374609470952728Keefe, D. [0000-0001-9377-431X]